Perspective Therapeutics, Inc. (NYSE:CATX) Director Acquires 38,145 Shares

Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III acquired 38,145 shares of the stock in a transaction dated Monday, March 31st. The shares were purchased at an average cost of $2.14 per share, with a total value of $81,630.30. Following the completion of the purchase, the director now owns 108,982 shares of the company’s stock, valued at approximately $233,221.48. The trade was a 53.85 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Perspective Therapeutics Stock Performance

NYSE:CATX opened at $2.05 on Thursday. The firm has a 50-day simple moving average of $2.85 and a two-hundred day simple moving average of $6.07. Perspective Therapeutics, Inc. has a fifty-two week low of $1.90 and a fifty-two week high of $19.05.

Analyst Upgrades and Downgrades

A number of research analysts have commented on CATX shares. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Royal Bank of Canada reduced their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Thursday, March 27th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. Finally, Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Perspective Therapeutics currently has a consensus rating of “Buy” and an average target price of $14.44.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CATX. FMR LLC boosted its position in shares of Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after buying an additional 5,370,392 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after purchasing an additional 355,685 shares during the last quarter. Deerfield Management Company L.P. Series C raised its holdings in shares of Perspective Therapeutics by 4.3% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock valued at $9,375,000 after purchasing an additional 120,991 shares during the last quarter. Octagon Capital Advisors LP boosted its holdings in Perspective Therapeutics by 62.1% in the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after purchasing an additional 882,528 shares during the last quarter. Finally, State Street Corp grew its position in Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the period. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.